ArticleACS omega2025
Integrating Magnetic Bead-Based SELEX with
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics.Signal transduction and targeted therapy · 2026Review
- Nanoparticles-assisted SELEX strategies for aptamer screening: a comprehensive review.Mikrochimica acta · 2026Review
- Aptamers in cancer therapy: Why has clinical translation lagged behind preclinical promise?Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify aptamers that bind with high affinity to transgelin-2 (TAGLN2), a potential diagnostic biomarker for a number of diseases, such as cancer and tuberculosis, that is associated with cellular stress. Aptamers targeting recombinant TAGLN2 were selected through magnetic bead-based systematic evolution of ligands by exponential enrichment (SELEX). DNA sequence analysis and Geneious software analysis identified 10 unique aptamer sequences that potentially bind to TAGLN2. A phylogenetic analysis of these sequences shows that these sequences clustered into two clades based on sequence similarity, with the sequences in one of the clades (consisting of 4 unique sequences) showing higher similarity to each other. The secondary structures of aptamer sequences (aptamers 1, 2, 7, and 9) from this highly conserved clade were predicted using the M-fold web server. The binding of two of these aptamer sequences (aptamer 7 and 9) to recombinantly expressed TAGLN2 was verified by microscale thermophoresis (MST). The dissociation constants for aptamers 7 and 9 were determined to be 18 ± 1 and 50 ± 2 nM, respectively.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.